Neumora Therapeutics, Inc. Common Stock (NMRA) — Financial statements
Income statement, balance sheet, and cash flow for Neumora Therapeutics, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 5 | 0.00↓100.0% | 0.67 | 0.00 | 0.00 | |
| Gross Profit | -5 | 0.00↑100.0% | -0.67 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 176↓12.4% | 201↑40.8% | 143↑36.2% | 105↓50.8% | 213 | |
| General & Administrative Expenses | 60↓3.9% | 63↑37.5% | 45↑46.1% | 31↑26.8% | 25 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.67 | 0.00 | 0.00 | |
| SG&A Expenses | 60↓3.9% | 63↑39.6% | 45↑44.0% | 31↑26.8% | 25 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 236↓10.4% | 263↑40.5% | 188↑38.0% | 136↓42.7% | 237 | |
| Total Costs & Expenses | 241↓8.5% | 263↑40.0% | 188↑38.5% | 136↓42.7% | 237 | |
| Operating Results | ||||||
| Operating Income | -241↑8.5% | -263↓40.0% | -188↓38.5% | -136↑42.7% | -237 | |
| Depreciation & Amortization | 0.21↓67.0% | 0.63↓5.5% | 0.67↑12.5% | 0.59↑10.4% | 0.54 | |
| EBITDA | -233↑11.2% | -263↓40.2% | -188↓38.6% | -135↑42.9% | -237 | |
| EBIT | -234↑11.3% | -263↓40.0% | -188↓38.5% | -136↑42.7% | -237 | |
| Interest & Other Income | ||||||
| Net Interest Income | 5↓74.3% | 20↑20.0% | 17↑264.2% | 5 | 0.00 | |
| Interest Income | 8↓58.1% | 20↑20.0% | 17↑264.2% | 5 | 0.00 | |
| Interest Expense | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -8 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 4↓78.1% | 20↑141.8% | -47↓1055.8% | 5↑45045.5% | 0.01 | |
| Income Before Tax | -237↑2.8% | -244↓3.4% | -236↓80.0% | -131↑44.8% | -237 | |
| Income Tax Expense | 0.13↓27.0% | 0.18↓33.6% | 0.27 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -237↑2.8% | -244↓3.3% | -236↓80.2% | -131↑44.8% | -237 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -237↑2.8% | -244↓3.3% | -236↓80.2% | -131↑44.8% | -237 | |
| Bottom-Line Net Income | -237↑2.8% | -244↓3.3% | -236↓80.2% | -131↑44.8% | -237 | |
| EPS (Basic) | -1.45↑5.2% | -1.53↓2.7% | -1.49↓73.3% | -0.86↑44.9% | -1.56 | |
| EPS (Diluted) | -1.45↑5.2% | -1.53↓2.7% | -1.49↓73.3% | -0.86↑44.9% | -1.56 | |
| Weighted Average Shares | 163↑2.5% | 159↑0.3% | 159↑4.5% | 152↑0.0% | 152 | |
| Weighted Average Diluted Shares | 163↑2.5% | 159↑0.3% | 159↑4.5% | 152↑0.0% | 152 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.